https://www.newslocker.com/en-us/profession/pharmaceutical/en-usCopyright (C) 2026 newslocker.comThu, 04 Jun 2026 07:06:00 +0200 This month's update covers new approvals across oncology, respiratory medicine, infectious disease, cardiology, and dermatology.Veppanu (vepdegestrant)
The FDA approved Veppanu for the treatment of adults with estrogen...]]>https://www.newslocker.com/en-us/profession/pharmaceutical/monthly-news-roundup-may-2026/Thu, 04 Jun 2026 07:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/monthly-news-roundup-may-2026/https://www.newslocker.com/en-us/profession/pharmaceutical/influenza-vaccine-effective-for-children-aged-2-to-5-years/Wed, 03 Jun 2026 22:59:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/influenza-vaccine-effective-for-children-aged-2-to-5-years/https://www.newslocker.com/en-us/profession/pharmaceutical/tezepelumab-reduces-need-for-oral-corticosteroids-in-adults-with-asthma/Wed, 03 Jun 2026 22:56:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/tezepelumab-reduces-need-for-oral-corticosteroids-in-adults-with-asthma/https://www.newslocker.com/en-us/profession/pharmaceutical/millions-on-medicaid-may-soon-have-to-prove-theyre-working-to-keep-coverage/Wed, 03 Jun 2026 18:12:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/millions-on-medicaid-may-soon-have-to-prove-theyre-working-to-keep-coverage/https://www.newslocker.com/en-us/profession/pharmaceutical/asco-modest-accuracy-seen-for-existing-breast-cancer-risk-prediction-models/Wed, 03 Jun 2026 18:01:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/asco-modest-accuracy-seen-for-existing-breast-cancer-risk-prediction-models/https://www.newslocker.com/en-us/profession/pharmaceutical/asco-app-facilitated-palliative-care-improves-hrqol-in-advanced-cancer/Wed, 03 Jun 2026 17:57:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/asco-app-facilitated-palliative-care-improves-hrqol-in-advanced-cancer/https://www.newslocker.com/en-us/profession/pharmaceutical/mailed-fit-kits-boost-colorectal-cancer-screening-across-racial-ethnic-groups/Wed, 03 Jun 2026 17:55:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/mailed-fit-kits-boost-colorectal-cancer-screening-across-racial-ethnic-groups/https://www.newslocker.com/en-us/profession/pharmaceutical/diagnostic-interviews-may-not-be-reliable-for-behavioral-health-diagnoses/Wed, 03 Jun 2026 17:53:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/diagnostic-interviews-may-not-be-reliable-for-behavioral-health-diagnoses/https://www.newslocker.com/en-us/profession/pharmaceutical/cardiometabolic-cardiovascular-complications-less-likely-with-hydroxychloroquine-in-dle/Wed, 03 Jun 2026 17:50:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/cardiometabolic-cardiovascular-complications-less-likely-with-hydroxychloroquine-in-dle/https://www.newslocker.com/en-us/profession/pharmaceutical/just-90-minutes-of-strength-training-a-week-linked-to-longer-life/Wed, 03 Jun 2026 16:02:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/just-90-minutes-of-strength-training-a-week-linked-to-longer-life/https://www.newslocker.com/en-us/profession/pharmaceutical/urine-test-can-detect-autism-study-says/Wed, 03 Jun 2026 12:30:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/urine-test-can-detect-autism-study-says/https://www.newslocker.com/en-us/profession/pharmaceutical/high-puff-vapes-become-more-toxic-over-time-study-says/Wed, 03 Jun 2026 12:15:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/high-puff-vapes-become-more-toxic-over-time-study-says/ About 70% of patients treated with teclistamab...]]>https://www.newslocker.com/en-us/profession/pharmaceutical/chemo-free-drug-tecvayli-shows-major-survival-remission-gains-in-relapsed-multiple-myeloma/Wed, 03 Jun 2026 12:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/chemo-free-drug-tecvayli-shows-major-survival-remission-gains-in-relapsed-multiple-myeloma/https://www.newslocker.com/en-us/profession/pharmaceutical/chemo-free-drug-shows-major-survival-remission-gains-in-relapsed-multiple-myeloma/Wed, 03 Jun 2026 12:00:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/chemo-free-drug-shows-major-survival-remission-gains-in-relapsed-multiple-myeloma/https://www.newslocker.com/en-us/profession/pharmaceutical/glp-1-drugs-like-ozempic-may-lower-breast-cancer-risk-by-about-30/Wed, 03 Jun 2026 11:45:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/glp-1-drugs-like-ozempic-may-lower-breast-cancer-risk-by-about-30/https://www.newslocker.com/en-us/profession/pharmaceutical/telehealth-booms-as-demand-for-glp-1s-surges-and-questions-mount-about-safety-oversight/Wed, 03 Jun 2026 11:30:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/telehealth-booms-as-demand-for-glp-1s-surges-and-questions-mount-about-safety-oversight/https://www.newslocker.com/en-us/profession/pharmaceutical/over-one-third-of-us-adults-report-more-than-one-sunburn-in-previous-12-months/Tue, 02 Jun 2026 23:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/over-one-third-of-us-adults-report-more-than-one-sunburn-in-previous-12-months/https://www.newslocker.com/en-us/profession/pharmaceutical/ats-early-nonadherence-to-cpap-does-not-predict-treatment-abandonment/Tue, 02 Jun 2026 23:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/ats-early-nonadherence-to-cpap-does-not-predict-treatment-abandonment/https://www.newslocker.com/en-us/profession/pharmaceutical/trump-signs-order-calling-for-fewer-childhood-vaccines/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/trump-signs-order-calling-for-fewer-childhood-vaccines/https://www.newslocker.com/en-us/profession/pharmaceutical/sacituzumab-govitecan-shows-encouraging-results-for-aggressive-endometrial-cancer/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-us/profession/pharmaceutical/sacituzumab-govitecan-shows-encouraging-results-for-aggressive-endometrial-cancer/